IST-MEL1 - Cell Line (ID:50020)
HMS LINCS ID: | 50020 |
Name: | IST-MEL1 |
Alternative Names: | |
LINCS ID: | LCL-1234 |
Alternative ID: | CLO_0006969 |
Parent Cell Line: | |
Reference Source: | Interlab Cell Line Collection (ICLC) HTL01006 |
Organism: | Homo sapiens |
Organ: | skin |
Tissue: | |
Cell Type: | epithelial-like |
Details of Cell Type: | |
Donor Sex: | male |
Donor Age: | |
Donor Ethnicity: | |
Donor Health Status: | |
Disease: | DOID:1909, malignant melanoma |
Details of Disease: | |
Production Details: | |
Genetic Modification(s): | none |
Known Mutations: | |
Citation Information for Mutations: | COSS907172 |
Verification Reference Profile: | |
Growth Properties: | adherent |
Recommended Culture Conditions: | ICLC growth medium: RPMI 1640 + 10% FBS + 2mM L-Glutamine; Freezing medium: Culture medium + 50% FBS + 10% DMSO; Split confluent cultures 1:2-1:4 using trypsin/EDTA; 37C, 5% CO2, mycoplasma negative, HOECHST and PCR |
Relevant Citations: | |
Usage Note: | |
Comments: | |
Date Publicly Available: | 2012-04-25 |
Most Recent Update: | 2016-04-04 |
Batch Information for HMSL50020-2:
HMS LINCS Batch ID: | 50020-2 |
Provider: | Center for Molecular Therapeutics (CMT; Massachusetts General Hospital) |
Provider Catalog ID: | MGH-8077 |
Provider Batch ID: | |
Source Information: | Obtained by Yangzhong Tang (Harvard Medical School) from the Center for Molecular Therapeutics (CMT; Massachusetts General Hospital) (contact: Cyril Benes). CMT previously had obtained the cells from the Wellcome Trust Sanger Institute. |
Date Received: | |
HMS QC Outcome: | |
Transient Modification(s): | |
Comments: | |
Date Publicly Available: | 2016-06-06 |
Most Recent Update: | 2016-07-12 |